INDIVIDUAL DOSE ADAPTATION OF ANTICANCER DRUGS

被引:41
作者
DESOIZE, B [1 ]
ROBERT, J [1 ]
机构
[1] FDN BERGONIE,BIOCHIM LAB,F-33076 BORDEAUX,FRANCE
关键词
ANTICANCER DRUGS; DOSE ADJUSTMENT; NEW THERAPEUTIC STRATEGY; PHARMACOKINETIC; PHARMACOLOGY;
D O I
10.1016/0959-8049(94)90304-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The dose of anticancer drugs is currently adjusted to the patient body surface area, although patients have different abilities to clear anticancer drugs. The dose adjustment to physiological functions permits major toxic accidents to be avoided. The adjustment to tumour drug content is considered, but for ethical or technical reasons, it cannot be used routinely The best criterion for the dose adjustment seems to be drug plasma concentration. The relationship between plasma concentration and efficacy may not be excellent, since it depends on the presence of resistant cells and on the blood how through the tumour. A relationship between plasma concentration and/or the area under the curve (AUC) with toxicity has been reported with all major anticancer drugs. Different methods of dose adjustment to the drug plasma concentration are reported. In conclusion, dose adjustment to the drug plasma concentration or to the AUC can improve the chemotherapy efficacy, while reducing toxicity.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 130 条
  • [91] LIMITED SAMPLING MODELS FOR DOXORUBICIN PHARMACOKINETICS
    RATAIN, MJ
    ROBERT, J
    VANDERVIJGH, WJF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) : 871 - 876
  • [92] RATAIN MJ, 1987, CANCER TREAT REP, V71, P935
  • [93] PARADOXICAL RELATIONSHIP BETWEEN ACETYLATOR PHENOTYPE AND AMONAFIDE TOXICITY
    RATAIN, MJ
    MICK, R
    BEREZIN, F
    JANISCH, L
    SCHILSKY, RL
    WILLIAMS, SF
    SMIDDY, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) : 573 - 579
  • [94] ADAPTIVE-CONTROL OF ETOPOSIDE ADMINISTRATION - IMPACT OF INTERPATIENT PHARMACODYNAMIC VARIABILITY
    RATAIN, MJ
    SCHILSKY, RL
    CHOI, KE
    GUARNIERI, C
    GRIMMER, D
    VOGELZANG, NJ
    SENEKJIAN, E
    LIEBNER, MA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (03) : 226 - 233
  • [95] PHARMACODYNAMICS IN CANCER-THERAPY
    RATAIN, MJ
    SCHILSKY, RL
    CONLEY, BA
    EGORIN, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) : 1739 - 1753
  • [96] RATAIN MJ, 1986, CANCER RES, V46, P4827
  • [97] RATAIN MJ, 1987, CANCER CHEMOTHERAPY, P12
  • [98] CREATININE CLEARANCE AS A PREDICTOR OF ULTRAFILTERABLE PLATINUM DISPOSITION IN CANCER-PATIENTS TREATED WITH CISPLATIN - RELATIONSHIP BETWEEN PEAK ULTRAFILTERABLE PLATINUM PLASMA-LEVELS AND NEPHROTOXICITY
    REECE, PA
    STAFFORD, I
    RUSSELL, J
    KHAN, M
    GILL, PG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (02) : 304 - 309
  • [99] PLATINUM-DNA ADDUCTS IN LEUKOCYTE DNA CORRELATE WITH DISEASE RESPONSE IN OVARIAN-CANCER PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY
    REED, E
    OZOLS, RF
    TARONE, R
    YUSPA, SH
    POIRIER, MC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (14) : 5024 - 5028
  • [100] REICH SD, 1978, PHARM THER C, V2, P239